Microbot Medical

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Braintree, MA.

MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.

Microbot Medical Stock Rises After Completing ACCESS-PVI Trial

U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinical trial.

Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025

Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for ACCESS-PVI human clinical trial for LIBERTY®.

Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024

Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.

Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform

Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.

Microbot Medical (MBOT) Gets Quality Certification for its System

The ISO 13485 certification is a validation of the Company's robust quality system The ISO 13485 certification is a validation of the Company's robust quality system

Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.

Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics

The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system

Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System

As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women's Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women's Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company's Pivotal Human Clinical Trial.

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

The first clinical case was performed at Brigham and Women's Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical System BRAINTREE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the completion of the first procedure in a patient utilizing its LIBERTY® Endovascular Robotic Surgical System.

Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial

Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.

Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial

Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY

Following the Company's recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial Following the Company's recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial

Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial

Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances

Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was delivered

Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial

HINGHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company's common stock at a purchase price of $1.50 per share of common stock . In addition, in a concurrent private placement, the Company has issued unregistered series F preferred investment options. The series F preferred investment options to purchase up to 3,133,338 shares of common stock have an exercise price of $1.50 per share and are immediately exercisable following issuance for a period of two years thereafter.

Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company's common stock at a purchase price of $1.50 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series F preferred investment options. The series F preferred investment options to purchase up to 3,133,338 shares of common stock have an exercise price of $1.50 per share and are immediately exercisable following issuance for a period of two years thereafter. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about June 4, 2024, subject to the satisfaction of customary closing conditions.

Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submission The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submission

Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial

The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel

Microbot Medical Shares Status Following Recent Geopolitical Events

ExScientia Ltd

Guardforce AI Co Ltd

Excitement over the prospects for artificial intelligence (AI) continues to be a significant driver for many stocks, including several of the so-called Magnificent Seven.

News for Microbot Medical Stock (MBOT)